Shitij Arora

Dr. Shitij Arora

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Closed access
PDF file
AYAnju Yadav
Anju Yadav
SVSridevi Vallabu
Sridevi Vallabu
SAShitij Arora
Shitij Arora
PTPranay Tandon
Pranay Tandon
DSDivya Slahan
Divya Slahan
Pravin C SinghalPravin C Singhal
Pravin C Singhal
Podocytes are an integral and important constituent of the glomerular filtration barrier (GFB) and are exposed to a higher concentrations of ANG II in diseased states; consequently, podocytes may accumulate oxidized proteins and damaged mitochondria. In the present study, we evaluated the effect of ANG II on the podocyte autophagic process, which is likely to be triggered in order to degrade unwanted proteins and damaged organelles. To quantitate the occurrence of autophagy, electron microscopic studies were carried out on control and ANG II-treated conditionally immortalized mouse podocytes (CIMPs). ANG II-treated cells showed a fivefold greater number of autophagosomes/field compared with control cells. This proautophagic effect of ANG II was inhibited by pretreatment with 3-methyladenine, an inhibitor of autophagy. ANG II also enhanced podocyte expression of autophagic genes such as LC3-2 and beclin-1. Since oxidative stress is often associated with the induction of autophagy, we examined the effect of ANG II on podocyte reactive oxygen species (ROS) generation. ANG II enhanced podocyte ROS generation in a time-dependent manner. To determine whether there is a causal relationship between ANG II-induced oxidative stress and induction of autophagy, we evaluated the effect of antioxidants on ANG II-induced autophagy. As expected, the proautophagic effect of ANG II was inhibited by antioxidants. We conclude that ANG II promotes podocyte autophagy through the generation of ROS.

21 September 2011 in Current Osteoporosis Reports
Verified
Journal Article
Closed access
PDF file
MAManasi Agrawal
Manasi Agrawal
SAShitij Arora
Shitij Arora
JLJianjun Li
Jianjun Li
RRRabin Rahmani
Rabin Rahmani
LSLi Sun
Li Sun
MZMone Zaidi
Mone Zaidi

17 February 2021 in Journal of Hospital Medicine
Verified
Journal Article
Closed access
PDF file
ZCZhu Cui
Zhu Cui
ZMZachary Merritt
Zachary Merritt
AAAndrei Assa
Andrei Assa
HMHashim Mustehsan
Hashim Mustehsan
ECErica Chung
Erica Chung
SAShitij Arora
Shitij Arora
BACKGROUND: Corticosteroids may be beneficial in a subset of patients with coronavirus disease 2019 (COVID‐19), but predictors of therapeutic response remain unknown. C‐reactive protein (CRP) is a routinely measured biomarker, and reduction in its levels after initiation of therapy may predict inpatient mortality.METHODS: In this retrospective cohort study, the charts of patients who were admitted to Montefiore Medical Center between March 10, 2020, and May 2, 2020 for the management of COVID‐19 were examined. Of all patients who met inclusion criteria, patients who received corticosteroid treatment were categorized as CRP responders (≥50% CRP level reduction) and CRP nonresponders (<50% CRP level reduction) based on change in CRP within 72 hours of corticosteroid treatment initiation. The outcomes of interest were two‐fold: (1) CRP response after treatment with corticosteroid, and (2) differences in mortality among patients with CRP response compared those without.RESULTS: Of 2,707 patients admitted during the study period, 324 received corticosteroid treatment. Of patients who received corticosteroid treatment, CRP responders had reduced risk of death compared with risk among CRP nonresponders (25.2% vs 47.8%; unadjusted odds ratio [OR], 0.37; 95% CI, 0.21‐0.65; P < .001). This effect remained strong and significant after adjustment for potential confounders (adjusted OR, 0.27; 95% CI, 0.14‐0.54; P < .001).CONCLUSION: Reduction in CRP by 50% or more within 72 hours of initiating corticosteroid therapy potentially predicts inpatient mortality. This may serve as an early biomarker of response to corticosteroid therapy in patients with COVID‐19.

1 November 2012 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
SAShitij Arora
Shitij Arora
Hemant GoyalHemant Goyal
Hemant Goyal
PAPrachi Aggarwal
Prachi Aggarwal
AKAtul Kukar
Atul Kukar

Verified
Journal Article
Open access
PDF file
KAKavya Atluri
Kavya Atluri
IAIris Aimlin
Iris Aimlin
SAShitij Arora
Shitij Arora
The current pandemic due to the SARS-CoV-2 virus has caused irreparable damage globally. High importance is placed on defining current therapeutics for Coronavirus Disease 2019 (COVID-19). In this review, we discuss the evidence from pivotal trials that led to the approval of effective therapeutics in the treatment and prevention of COVID-19. We categorize them as effective outpatient and inpatient management strategies The review also attempts to contextualize the efficacy of therapeutics to the emerging variants. Vaccines, which remain the most effective prevention against hospitalization and deaths is not included in this review.

1 September 2010 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Open access
PDF file
JMJoannna Mikulak
Joannna Mikulak
STS. Teichberg
S. Teichberg
SAShitij Arora
Shitij Arora
DKD. Kumar
D. Kumar
AYA. Yadav
A. Yadav
Pravin C SinghalPravin C Singhal
Pravin C Singhal
Human immunodeficiency virus (HIV)-1 has been demonstrated to contribute to the pathogenesis of HIV-associated nephropathy. In renal biopsy studies, podocytes have been reported to be infected by HIV-1. However, the mechanism involved in HIV-1 internalization into podocytes is not clear. In the present study, we evaluated the occurrence of HIV-1 internalization into conditionally immortalized human podocytes and the mechanism involved. Human podocytes rapidly internalized R5 and X4 HIV-1 primary strains via an endocytosis-dependent pathway, without establishing a productive infection. The HIV-1 internalization was dendritic cell-specific ICAM-3-grabbing nonintegrin (DC-SIGN) receptor mediated. The role of DC-SIGN was confirmed by using specific blocking antibodies and transfection with small interfering (si) RNA/DC-SIGN. Since podocyte HIV-1 trafficking was not altered by pH-modulating agents, it appeared that HIV-1 routing occurred through nonacid vesicular compartments. Interestingly, transfection of podocytes with neither siRNA/caveolin-1 nor siRNA/clathrin heavy chain inhibited podocyte viral accumulation. Thus it appears that clathrin-coated vesicles and caveosomes may not be contributing to HIV-1-associated membrane traffic.